Journal article
Molecular mechanisms underlying the N-methyl-D-aspartate receptor antagonists: Highlighting their potential for transdiagnostic therapeutics
Progress in Neuro-Psychopharmacology & Biological Psychiatry, Vol.119, pp.1-8
2022
PMID: 35878675
Appears in Thompson Institute Research Collection
Abstract
The so-called "psychedelic renaissance" has stimulated expanded interest in several classes of drugs that appear to possess transdiagnostic effects in the treatment of mental health disorders, specifically. N-methyl-D-aspartate receptor (NMDAR) antagonists are one such class with diverse therapeutic potential. NMDARs mediate excitatory postsynaptic signalling in the central nervous system (CNS) and are integral to normal neurobiological processes including neuronal development, synaptic transmission, and plasticity, and thus involved in learning and memory. However, NMDAR hyper-function is also implicated in acute CNS trauma, neuropsychiatric and neurodegenerative disorders, as well as chronic pain. The complex structure of NMDARs permits several locations for therapeutic inhibition, making these receptors a potential target for multiple drugs which modulate them in different ways. NMDAR antagonists, which may be competitive, non-competitive, or uncompetitive, either block glutamate from binding the receptor or modulate the response to glutamate binding. Despite longstanding concerns about side effects of NMDAR antagonists, recent research suggests that, when appropriately used, these agents have favourable safety profiles. Furthermore, their fast-acting mechanism of action, resulting in rapid effects compared to other therapeutic agents, makes them a promising class of drugs that may yield effective therapeutics for multiple CNS disorders.
Details
- Title
- Molecular mechanisms underlying the N-methyl-D-aspartate receptor antagonists: Highlighting their potential for transdiagnostic therapeutics
- Authors
- Christina Driver (Author) - University of the Sunshine Coast, Queensland, Thompson InstituteTimothy N W Jackson (Author) - The University of MelbourneJim Lagopoulos (Author) - University of the Sunshine Coast, Queensland, Thompson InstituteDaniel Hermens (Author) - University of the Sunshine Coast, Queensland, Thompson Institute
- Publication details
- Progress in Neuro-Psychopharmacology & Biological Psychiatry, Vol.119, pp.1-8
- Publisher
- Elsevier Inc.
- Date published
- 2022
- DOI
- 10.1016/j.pnpbp.2022.110609
- ISSN
- 1878-4216
- PMID
- 35878675
- Organisation Unit
- Thompson Institute
- Language
- English
- Record Identifier
- 99659498302621
- Output Type
- Journal article
Metrics
45 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Web Of Science research areas
- Clinical Neurology
- Neurosciences
- Pharmacology & Pharmacy
- Psychiatry
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: SDGs from InCites